Orthocell Ltd (ASX:OCC, OTC:ORHHF) has reported that its Remplir™ nerve repair device has been used in 23 surgical procedures on Ukrainian soldiers injured in combat, marking an important real-world application of the technology in frontline trauma care.
The update follows a humanitarian delivery of Remplir to Ukraine in April 2025, with the company now receiving confirmation that the device has been successfully deployed by local surgeons in both primary and secondary nerve repair procedures.
“In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant. The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution,” Orthocell managing director Paul Anderson said.
Real-world use highlights impact on battlefield injuries
The use of Remplir in active conflict conditions underscores its role in treating severe nerve injuries sustained during combat, where rapid and effective surgical intervention is critical to preserving function and mobility.
Designed to connect, protect and cap severed nerves, the device has been applied across 23 patients, with surgeons reporting positive feedback on its handling and clinical performance.
The outcomes demonstrate the product’s suitability for major trauma settings, particularly in defence environments where injuries are often complex and time-sensitive.
Remote training enables deployment in conflict zone
A key aspect of the program has been the ability to train surgeons remotely, enabling adoption of the device despite the challenges of operating in a war zone.
Ukrainian surgeons were trained via video by Orthocell’s key opinion leader Dr Alex O’Beirne, with the successful rollout following remote instruction highlighting the accessibility and practicality of the technology in constrained environments.
The device’s portability, room-temperature storage and three-year shelf life have also supported its use in field and hospital settings, where logistics can limit access to specialised medical equipment.
Program lays groundwork for broader defence engagement
Orthocell will continue working with Ukrainian surgeons to monitor patient outcomes and, where possible, collect clinical data from the procedures.
The company expects this real-world evidence to support ongoing discussions with defence organisations globally, as it evaluates further opportunities to expand the use of Remplir in military and trauma care settings.
The program represents an early demonstration of the device’s application in conflict-related injuries, with the results providing a potential pathway for broader adoption across defence and emergency medicine sectors.